Bladder cancer accounts for nearly 600,000 new cases and over 200,000 deaths annually worldwide. Approximately 25% of diagnoses correspond to muscle-invasive disease ...
Lee et al, 1 comprising authors from a number of institutions, published a retrospective observational study conducted on 147 consecutive patients who underwent endoscopic enucleation of the prostate ...
Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...
Sophia Coraci discusses an analysis of 104 treatment-naive prostate cancer patients correlating PSMA PET SUVmax with Decipher genomic classifier scores. PSMA PET imaging occurred within 35 days of ...
Ananya Choudhury reviews radiation therapy for non-muscle invasive bladder cancer, citing 1990s UK trials showing overlapping Kaplan-Meier curves between radiotherapy and standard care. Modern ...
Thomas Powles presents IZABRIGHT, a global randomized Phase III trial testing izalontamab brengitecan, a dual HER1/HER3 antibody-drug conjugate with topoisomerase payload, versus platinum-based ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients - Paul Nguyen
Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-analyzed digital pathology from prostatectomy specimens. Validation using RTOG ...
Low-Intensity Shockwave Therapy (LiSWT) has emerged as a safe, non-invasive treatment option for erectile dysfunction. Reports regarding efficacy are heterogeneous at best, and both the AUA (American ...
Neuroendocrine tumors (NETs) of the prostate are a rare but clinically aggressive subset of prostate cancer. They may occur de novo or more commonly arise through treatment-related ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results